NUCLIDIUM Featured in BioCentury Emerging Company Profile
Our CEO Leila Jaafar recently sat down with BioCentury Reporter Tierney Baum to discuss Nuclidium’s unique copper-based approach to establish scalable manufacturing of radioligand therapeutics and diagnostics.
Access the article to learn more on how we aim to address current limitations in cancer diagnosis and treatment, as well as bottlenecks in production and global supply of radiopharmaceuticals. We are advancing our Copper-61- and Copper-67-based radiotheranostic programs, with our therapeutic candidates for PSMA-positive metastatic prostate cancer and HR+/HER2-metastatic breast cancer about to enter Phase 1 evaluation.
Read the full article online at: https://www.biocentury.com/article/657263/nuclidium-betting-on-copper-isotopes-for-scalable-radiopharma-supply-chains
